# Design and Rationale of the COLT Study

Study · id `cardio:ct-nct07432529` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07432529](<https://clinicaltrials.gov/study/NCT07432529>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07432529

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 940 participants.

## Technical summary

Registry record NCT07432529. Randomized; quadruple masking; primary purpose prevention. Start 2026-06-01 (anticipated); primary completion 2027-06-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 940 participants (planned count; ClinicalTrials.gov record NCT07432529, source copy `cardio:ctgov-nct07432529-2026-02-25`, retrieved 2026-10-31)
- Planned start: 2026-06-01 (anticipated) (ClinicalTrials.gov record NCT07432529, source copy `cardio:ctgov-nct07432529-2026-02-25`, retrieved 2026-10-31)
- Primary completion: 2027-06-01 (anticipated) (ClinicalTrials.gov record NCT07432529, source copy `cardio:ctgov-nct07432529-2026-02-25`, retrieved 2026-10-31)
- Completion: 2027-06-01 (anticipated) (ClinicalTrials.gov record NCT07432529, source copy `cardio:ctgov-nct07432529-2026-02-25`, retrieved 2026-10-31)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07432529-2026-02-25`, retrieved 2026-10-31)

## The registry's words

- Brief title: Design and Rationale of the COLT Study
- Acronym: COLT
- Condition: Venous Thrombosis Deep (Limbs)
- Condition: Post-thrombotic Syndrome
- Condition: Venous Thromboembolism (VTE)
- Condition: Venous Insufficiency
- Intervention (Drug): Colchicine 0.5 MG Oral Tablet
- Intervention (Drug): Placebo
- Lead sponsor: Azienda Sanitaria Locale ASL 6, Livorno
- Lead sponsor class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Deep vein thrombosis (`cardio:deep-vein-thrombosis`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Colchicine (`cardio:colchicine`)

## Provenance

Content hash: c114249751eb4e50ccfdba65ec37de239f545a353051dade927b746f4a6c7d73
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
